EIK1005-002:進行性固形腫瘍(マイクロサテライト不安定性高(MSI-H)腫瘍を含む)患者を対象とした、Wernerヘリカーゼ阻害剤EIK1005の単剤療法およびペムブロリズマブとの併用療法を評価する臨床研究
進行性固形腫瘍を有する参加者(マイクロサテライト不安定性高(MSI-H)またはミスマッチ修復欠損(dMMR)腫瘍を有するチェックポイント阻害剤未治療参加者を含む)における、単剤療法およびペムブロリズマブとの併用療法としてのEIK1005の多施設共同、多パート、第1/2相試験
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
調査の概要
状態
条件
詳細な説明
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Ana C Mamede, PharmD
- 電話番号:347-806-4584
- メール:mamedea@eikontx.com
研究連絡先のバックアップ
- 名前:Krishna Kaza
- メール:kazak@eikontx.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90027
- 募集
- California Research Institute (CRI)
-
-
Florida
-
Doral、Florida、アメリカ、33172
- 募集
- Omnicure Clinical Research
-
Hialeah、Florida、アメリカ、33013
- 募集
- Bioresearch Partner
-
Plantation、Florida、アメリカ、33322
- 募集
- Florida Clinical Trials Group
-
Tamarac、Florida、アメリカ、33321
- 募集
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown、New Jersey、アメリカ、07960
- 募集
- Morristown Medical Center
-
-
New York
-
Lake Success、New York、アメリカ、11042
- 募集
- START New York-Long Island
-
New York、New York、アメリカ、10022
- 募集
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- 募集
- START Dallas Fort Worth
-
Houston、Texas、アメリカ、77030
- 募集
- University of Texas MD Anderson Cancer Center
-
-
-
-
-
Rome、イタリア、00128
- 募集
- Campus Bio-Medico di Rome University
-
-
-
-
New South Wales
-
Saint Leonards、New South Wales、オーストラリア
- まだ募集していません
- GenesisCare North Shore (Oncology)
-
Waratah、New South Wales、オーストラリア
- 募集
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat、Victoria、オーストラリア
- 募集
- Grampians Health
-
Camperdown、Victoria、オーストラリア
- 募集
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston、Victoria、オーストラリア
- 募集
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston、Victoria、オーストラリア、3199
- 募集
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Linz、オーストリア、4020
- 募集
- Ordensklinikum Linz Elisabethinen
-
-
-
-
-
Singapore、シンガポール、119074
- 募集
- National University Hospital (NUH)
-
-
Central Region
-
Singapore、Central Region、シンガポール、168583
- 募集
- National Cancer Centre Singapore (NCCS)
-
-
-
-
-
Barcelona、スペイン、08023
- 募集
- START - Barcelona
-
Logroño、スペイン、26006
- 募集
- START Rioja - Hospital de San Pedro
-
Madrid、スペイン、28233
- 募集
- NEXT Madrid HUQSM
-
Zaragoza、スペイン、50009
- 募集
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma、Balearic Islands、スペイン、07120
- 募集
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、8036
- 募集
- Hospital Clinic Barcelona
-
-
-
-
-
Berlin、ドイツ、13125
- 募集
- Helios Klinikum Berlin-Buch
-
Hamburg、ドイツ、22297
- 募集
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf、Bavaria、ドイツ、94469
- 募集
- DONAUISAR Klinikum
-
-
-
-
-
Wellington、ニュージーランド
- 募集
- Health New Zealand
-
-
Manawatu
-
Roslyn、Manawatu、ニュージーランド、4414
- 募集
- Palmerstone North Hospital
-
-
-
-
-
Oslo、ノルウェー、0379
- 募集
- Oslo University
-
-
-
-
-
Kuopio、フィンランド、70210
- 募集
- Kuopio University Hospital
-
-
-
-
Rhone
-
Pierre-Bénite、Rhone、フランス、69310
- 募集
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Brussels、ベルギー、1020
- 募集
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Lisbon、ポルトガル、1649-028
- 募集
- Hospital de Santa Maria
-
Loures、ポルトガル、2674-514
- 募集
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto、ポルトガル、4200
- 募集
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon、Lisbon District、ポルトガル、1500-650
- 募集
- Hospital da Luz Lisboa
-
-
-
-
-
Krakow、ポーランド、31-864
- 募集
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz、ポーランド、90-338
- 募集
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin、West Pomeranian Voivodeship、ポーランド、70-419
- 募集
- One Day Med
-
-
-
-
-
Seoul、韓国、02841
- 募集
- Korea University Anam Hospital
-
Suwon、韓国、16499
- 募集
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan、Busan、韓国、48108
- 募集
- Inje University-Haeundae Paik Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
実験的:Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
実験的:Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
時間枠:21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
時間枠:From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
時間枠:Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
時間枠:Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
時間枠:Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
時間枠:Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
時間枠:Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
時間枠:Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
時間枠:Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
時間枠:Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
時間枠:Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Nilou Mobashery, MD、Eikon Therapeutics, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- EIK1005-002
- 2026-525248-13-00 (Ctis)
- KEYNOTE-G56 (その他の識別子:Merck Sharp & Dohme LLC)
- MK-3475-G56 (その他の識別子:Merck Sharp & Dohme LLC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。